Simon Jeremy Fry has been appointed as a Director of Conduit Pharmaceuticals Inc, effective December 18, 2024. This information was disclosed in a Form 3 filing with the United States Securities and Exchange Commission, indicating an initial statement of beneficial ownership of securities.The filing reveals that Fry directly owns 200,000 shares of Conduit Pharmaceuticals' common stock. This substantial shareholding suggests a significant commitment to the company and aligns the new director's interests with those of other shareholders.The Form 3 was signed by Fry on December 20, 2024, two days after the event requiring the statement. No derivative securities were reported in the filing, indicating that Fry's ownership is currently limited to common stock.

Simon Jeremy Fry has been appointed as a Director of Conduit Pharmaceuticals Inc, effective December 18, 2024. This information was disclosed in a Form 3 filing with the United States Securities and Exchange Commission, indicating an initial statement of beneficial ownership of securities.The filing reveals that Fry directly owns 200,000 shares of Conduit Pharmaceuticals' common stock. This substantial shareholding suggests a significant commitment to the company and aligns the new director's interests with those of other shareholders.The Form 3 was signed by Fry on December 20, 2024, two days after the event requiring the statement. No derivative securities were reported in the filing, indicating that Fry's ownership is currently limited to common stock.